ERBB2 and breast cancer: This study was designed to assess whether the addition of trastuzumab in an early phase in combination with taxanes may increase NC-induced pCR rates in patients with locally advanced HER2-overexpressing BC without the burden of cardiac dysfunction related to anthracyclines.